GLP-1 Weight Loss in Corinth, MS: What to Expect, How It Works, and a 12-Week Roadmap

She had tried everything. Three rounds of a national chain weight-loss program in her thirties. Keto for nine months in 2019 — lost twenty-two pounds, gained back twenty-eight. A spin class habit she kept up religiously for two years that built her cardio but left her body looking essentially the same. Two different "metabolism reset" supplements ordered off Instagram. Intermittent fasting until her gallbladder started complaining. A short, miserable run with phentermine that left her so jittery she couldn't sleep. By the time she walked through the doors of our new clinic on South Harper Road in Corinth, she'd carried the same forty-five extra pounds for eleven years and was, in her own words, "tired of being tired about it."

What she didn't know walking in — and what most patients in Alcorn County don't know walking into their first GLP-1 consult — is that for the first time in the history of obesity medicine, we have tools that actually work. Not "work for a few months and then your body fights back." Not "work if you have iron willpower and never eat at a restaurant again." Actually work. The kind of work where the appetite signals that have been screaming at you since you turned thirty just... quiet down. Where the food noise that ran in the background of every meeting and every drive home stops. Where the scale moves and keeps moving, not because you're punishing yourself, but because your biology finally lets you stop fighting it.

That's what GLP-1 medications do. And in the two weeks since we opened the doors of Impact Health Corinth, the question we've been getting more than any other is some version of: "Is this going to work for me, and what does it actually look like?"

This is the long answer. We're going to walk through what GLP-1 medications actually are, how they work in plain-English biology, who's a good candidate and who isn't, the difference between semaglutide and tirzepatide, the full lab workup we do before anyone starts, and — the part most patients want most — a week-by-week, twelve-week roadmap of what your first three months should look like. We'll cover side effects honestly, we'll talk about the food and fitness pillars that decide whether you keep the weight off, and we'll explain why we use Styku 3D body scanning instead of just the scale. Then we'll cover maintenance, our cash-pay model, what walking into the Corinth clinic looks like, and we'll close with a long FAQ that answers the questions you came in with and the ones you didn't think to ask yet.

Settle in. This is the article we wish every Northeast Mississippi patient could read before their first appointment. If you'd rather skip the reading and just talk to someone, call us at 662-331-6366 or book a consult. Otherwise, let's get into it.

What GLP-1 Medications Actually Are

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut already makes — has been making your entire life — every time food hits your small intestine. Healthy people produce GLP-1 in proportional amounts in response to meals, and that hormone does several quiet, useful jobs: it tells your pancreas to release insulin, it tells your liver to ease off on glucose production, it slows down how fast food leaves your stomach, and it sends a message to a part of your brain (the hypothalamus, mostly, and some reward-circuit areas) that says, "We're full. We're done. Stop thinking about the bag of chips in the pantry."

That's the natural version. The medications we use — semaglutide, tirzepatide, and the newer compounds in development — are essentially synthetic GLP-1 analogs. They look enough like the natural hormone to bind to the same receptors, but they're engineered to last longer in the bloodstream (the natural version lasts about two minutes; semaglutide hangs around for a week), and the newer compounds bind to additional receptors that amplify the effect.

The class started in diabetes care more than fifteen years ago. The original version, exenatide, came on the market in 2005. Liraglutide followed. Then semaglutide, originally branded as Ozempic for diabetes and Wegovy for weight loss, fundamentally changed the conversation. Tirzepatide — branded Mounjaro for diabetes and Zepbound for weight loss — went further by being a dual agonist that hits both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual action is a real upgrade, not a marketing spin: in head-to-head trials, tirzepatide produces meaningfully more weight loss than semaglutide at comparable durations.

What's coming next is even more interesting. Tri-agonists like retatrutide hit GLP-1, GIP, and glucagon receptors. Oral versions of semaglutide are widely available. New combinations and dosing schedules are in trials right now. The class is moving fast, and what we're prescribing today is meaningfully better than what existed three years ago.

How GLP-1s Work, in Plain Language

If you remember nothing else from this section, remember these four mechanisms:

Slowed gastric emptying. Your stomach holds onto food longer. A meal that used to clear in ninety minutes might now take three or four hours. The practical effect: you feel full faster while you're eating, and you stay full longer after.
Increased satiety signaling. The hypothalamus gets a stronger "we're satisfied" signal earlier in the meal. Most patients describe this as their internal "stop" sign coming up after a smaller portion than they're used to.
Improved blood sugar regulation. Insulin response gets sharper, glucagon (the hormone that raises blood sugar) gets dialed back, and the post-meal blood sugar spike flattens out. This is why GLP-1s started in diabetes care — they're remarkably good at this.
Reduced food noise. This is the one patients talk about the most, and the one science is still catching up on. The reward circuits that make a chocolate bar at the gas station feel hard to resist quiet down. Patients describe it as their relationship to food changing — not gone, just calmer. Food becomes fuel and pleasure, not a constant negotiation.

That last one is hard to describe until you experience it, and it's part of why we say GLP-1s aren't really "appetite suppressants" the way phentermine or amphetamine-class drugs are. Phentermine yells. GLP-1 just... turns down the volume.

There's a fifth mechanism worth mentioning briefly, because it's where the next generation of these drugs is heading: GIP receptor activation. GIP is another gut hormone, and on its own it doesn't do much for weight. But combined with GLP-1 — which is what tirzepatide does — it appears to enhance the satiety signal, improve insulin response further, and reduce the dose of GLP-1 needed to achieve the same effect. Some animal data suggests GIP also affects fat cell biology directly, possibly making fat cells more metabolically efficient and less prone to storing excess energy. The science is still developing here, but the dual-agonist clinical results speak for themselves: more weight loss, often with less proportional side-effect burden, at therapeutic doses.

One more practical note about how GLP-1s feel from the inside: most patients describe the first few weeks as their relationship to food simply changing. Not gone — they still enjoy food, still look forward to meals, still go out to dinner. But the urgency around food, the constant background calculation about the next snack or whether to order dessert, fades. Patients who have struggled with weight their entire adult lives often describe this as the single most surreal part of the experience. "I forgot to eat lunch and I'm fine" is something many of our patients say within the first month — and for someone who has spent twenty years organizing their day around hunger, that sentence is a small revolution.

Who's a Candidate for GLP-1 Therapy?

The textbook criteria for GLP-1 weight-loss therapy are a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, prediabetes, sleep apnea, fatty liver, polycystic ovary syndrome, certain types of dyslipidemia, or osteoarthritis aggravated by weight). That's the formal answer.

The honest answer is more nuanced. We see people at BMI 26 who carry their weight badly — a lot of visceral fat, a stubborn waistline, an A1c creeping toward prediabetic — who benefit enormously. We see people at BMI 32 who are otherwise metabolically healthy and just want to lose weight for quality of life and mobility. The clinical decision is always individualized, and it's based on more than just a number on a chart.

What matters most in our consult:

Is your weight actively harming your health, your mobility, or your quality of life?
Have you tried lifestyle changes already? You don't have to have "earned" the medication, but understanding what you've tried helps us avoid repeating what didn't work.
Are there comorbidities (diabetes, prediabetes, hypertension, sleep apnea, NAFLD) that are actively progressing?
Are you ready for a real protocol — labs, follow-ups, food adjustments, body comp tracking — or are you looking for a magic shot? GLP-1s are powerful, but they're not magic, and the patients who do best are the ones who understand that going in.

If you're unsure where you fall, the first consult will sort it out. A lot of patients walk in convinced they don't qualify and walk out with a clear picture of why they do. The reverse also happens — sometimes the right answer is "let's address your sleep, your thyroid, and your insulin sensitivity first, and revisit GLP-1 in three months." That's a real answer too. Schedule a consult at /book or call 662-331-6366.

Who's NOT a Great Candidate

This part matters. GLP-1 medications carry specific contraindications, and we screen for every one of them before anyone gets a prescription. The list isn't long, but each item on it is a hard stop, not a soft one.

Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 receptor agonists have been associated with thyroid C-cell tumors in rodent studies. The translation to humans isn't fully settled, but personal or family history of MTC is a contraindication for the entire class.
Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Same reasoning — MEN2 is associated with MTC, and we don't prescribe to anyone with this diagnosis.
History of pancreatitis. GLP-1s have been associated with rare cases of pancreatitis. A history of acute or chronic pancreatitis is a contraindication, and patients with significant gallstone disease or other pancreatitis risk factors get extra scrutiny.
Pregnancy or active attempts to conceive. GLP-1 medications are not safe in pregnancy. Any patient who is pregnant, planning to become pregnant in the near term, or actively trying to conceive should not be on these medications. We typically recommend stopping the medication at least two months before attempted conception.
Severe gastroparesis or other major motility disorders. Because GLP-1s slow gastric emptying, they can dramatically worsen pre-existing gastroparesis.
Type 1 diabetes (without specialist co-management). Possible in carefully managed cases, but not something we initiate without coordination with the patient's endocrinologist.
Severe end-stage kidney or liver disease. Case-by-case.
Unstable eating disorder history. Patients with active or recently active anorexia, bulimia, or severe restrictive eating need to be in active care with a qualified specialist before we'd consider GLP-1 therapy. The medications can mask underlying patterns we'd rather see addressed first.

This isn't an exhaustive list, but it covers the major ones. The intake form and the labs catch most of these — and the in-person consult catches the rest. If you have any of these in your history and want to talk through whether GLP-1 makes sense for you, call us at 662-331-6366.

Semaglutide vs. Tirzepatide: A Real Comparison

This is the question we get more than any other: which one should I be on? The honest answer is "it depends," but the deciding factors are usually consistent. Here's how we think about it.

Semaglutide: The Established Workhorse

Semaglutide is a single-receptor agonist — it binds only to GLP-1 receptors. It's been around longer, has the largest body of safety data, and produces excellent weight loss results: in the major STEP trials, average weight loss at 68 weeks landed around 14-15% of starting body weight at the highest doses, with substantial subsets achieving 20% or more.

Strengths:

Long track record. Hundreds of thousands of patient-years of data.
Excellent for cardiovascular risk reduction (the SELECT trial established meaningful cardiovascular benefit independent of weight loss).
Generally well-tolerated. Side effects are predictable.
Often more readily available, both branded and compounded.
Slightly lower cost ceiling, in most cases.

Weaknesses:

Plateau more common around the 10-12% weight-loss mark for some patients.
Doesn't address GIP receptor pathways at all.
For patients with significant insulin resistance or metabolic syndrome, tirzepatide may have a meaningful edge.

Tirzepatide: The Dual Agonist

Tirzepatide hits both GLP-1 and GIP receptors. The combination matters. In the SURMOUNT-1 trial, average weight loss at 72 weeks at the highest dose was about 22.5% of starting body weight — meaningfully higher than semaglutide's results in comparable populations. Head-to-head trials (SURMOUNT-5, published recently) have confirmed the edge.

Strengths:

Higher average weight loss at top doses.
Often more effective for patients with insulin resistance, metabolic syndrome, or type 2 diabetes.
Some patients report less plateau behavior.
Useful as a switch option for patients who plateau on semaglutide.

Weaknesses:

Newer molecule, less long-tail safety data (still years of data, just less than sema).
Side effect profile can be slightly more pronounced at higher doses, particularly nausea and constipation.
Generally more expensive at the top doses.
Branded availability has been historically tighter.

How We Actually Choose

Most of our new patients in Corinth start with semaglutide unless one of these factors pushes us toward tirzepatide:

Significant insulin resistance, A1c above 6.0, or active metabolic syndrome.
Higher BMI (35+) where the goal weight loss is in the 20%+ range and we want every advantage.
Patient has tried semaglutide previously and plateaued.
Patient strongly prefers tirzepatide after we walk through the differences and the cost trade-off doesn't bother them.

The deeper truth is that both work. Both work well. The patient who picks the "wrong" one and follows the protocol consistently will outperform the patient who picks the "right" one and skips doses, eats poorly, and never lifts a weight. Adherence and lifestyle are far more important than which specific molecule you start on.

The Lab Workup Before You Start

We don't write a GLP-1 prescription without baseline labs. There are a few reasons for this. First, we need to rule out the contraindications above. Second, we want to know what we're working with metabolically — not just to clear you for treatment, but to know what to track over the next year. Third, weight loss medications affect a lot of systems, and we want a real before-and-after picture.

Here's the standard panel we run on adult patients starting GLP-1 therapy at our Corinth clinic. You can read more about our lab panels on the services page, but this is the working version:

Comprehensive Metabolic Panel (CMP). Kidney function (BUN, creatinine, eGFR), liver enzymes (AST, ALT), electrolytes, glucose. Baseline organ function.
Complete Blood Count (CBC). Catches anemia, infection, and a few other things that can masquerade as fatigue.
Hemoglobin A1c. Three-month average blood sugar. Critical baseline. Many patients are surprised to find they're already prediabetic.
Lipid panel. Total cholesterol, HDL, LDL, triglycerides. We'll watch this improve.
Fasting insulin. The single most underused lab in primary care. Tells us about insulin resistance long before A1c does.
HOMA-IR (calculated from fasting glucose and insulin). A direct insulin resistance score.
Full thyroid panel. TSH, free T4, free T3, sometimes reverse T3 and antibodies. Hypothyroidism masquerades as weight-loss resistance more often than people realize.
Sex hormone panel. For men: total and free testosterone, estradiol, SHBG, LH, FSH, prolactin. For women: estradiol, progesterone, LH, FSH, DHEA-S, total and free testosterone, SHBG, depending on cycle phase and menopausal status. Hormone optimization and weight loss are deeply intertwined.
Vitamin D, B12, ferritin. Common deficiencies that affect energy and metabolism.
hs-CRP. Inflammation marker.
Lipase. Pancreatic baseline.

On top of the bloodwork, we do a Styku 3D body composition scan at baseline. We'll come back to why this matters in a separate section, but for now: the scale tells you what you weigh; the Styku tells you whether the weight you're losing is fat or muscle, where on your body it's coming off, and whether your body shape is actually changing in the direction you want.

The lab visit takes about thirty minutes. Results come back in 3-5 business days, and we sit down with you to walk through everything before you start medication. No "we'll just call you if something's wrong" — you get the full picture.

The 12-Week Roadmap

This is the section most patients want first. We've put it later because the context above changes how you read it, but here it is: a week-by-week walkthrough of what your first twelve weeks on GLP-1 therapy at our Corinth clinic should look like. Individual experiences vary — that's not a disclaimer, it's a fact — but this is the typical arc.

Week 0: Consult, Labs, Baseline

Initial consult. We review your history, goals, lifestyle, prior weight-loss attempts, and any contraindications. We discuss medication options and answer questions.
Lab draw. Full panel as described above.
Baseline Styku scan. Body fat percentage, lean mass, waist circumference, hip-to-waist ratio, regional fat distribution.
Baseline weight, height, blood pressure, resting heart rate.
Initial photos (front, side, back) for visual progress tracking. These are kept private.
Food and movement baseline. Not a strict diet plan yet — we want to see where you're starting.

Week 0 isn't about restriction. It's about measurement. The work hasn't started yet; we're just getting clear on the starting line.

Week 1: First Dose

First injection. For semaglutide, we start at 0.25 mg weekly. For tirzepatide, 2.5 mg weekly.
You'll inject yourself, subcutaneously, into the abdomen, thigh, or upper arm. We teach you how at the in-person visit. It uses a very thin needle and most patients describe it as "barely a pinch."
Expect some nausea or stomach unsettlement starting 24-72 hours after the first dose. For most patients this is mild. For some it's more pronounced. If it's severe, call us.
Hydration, hydration, hydration. The single most underrated tool in the first week.
Food: smaller portions, more protein, less fried/fatty food. Greasy meals are the fastest way to make the first week miserable.
What to track: any symptoms, any food that didn't sit well, your weight (once at the start, once at the end of the week), your sleep.

Most patients lose 1-3 pounds in the first week. Some of that is water; some of that is the appetite suppression starting to bite. Don't get attached to the number yet.

Week 2: Adjusting

Second injection. Same dose as week 1.
Side effects, if any, often peak around days 2-4 after each weekly dose. By the end of week 2 most patients have a sense of their body's pattern.
Food noise should already be quieter. Most patients notice the change by the end of week 2.
Begin establishing a consistent eating window. Three meals, modest snack if needed, no grazing all day.
Start a basic walking habit if you don't have one. 20-30 minutes daily, no heroics.

Week 3: Stabilizing

Third injection at the same starting dose.
By now, the rhythm is clearer. You know which days after the shot you feel a little off, you know what foods are easy and which aren't.
Set a hard floor on protein intake. Aim for 0.7-1.0 grams of protein per pound of goal body weight, daily. This is the single most important number for protecting muscle while you lose fat.
Add light resistance training if you haven't already. Even bodyweight squats, push-ups, and rows three times a week.

Week 4: First Dose Escalation

For semaglutide, we move from 0.25 mg to 0.5 mg weekly. For tirzepatide, from 2.5 mg to 5 mg weekly.
Side effects often re-intensify briefly with each escalation. Same playbook: hydration, smaller portions, lower-fat meals, give it 3-5 days to settle.
Weight loss usually picks up noticeably here. Many patients see 4-8 pounds total off by the end of week 4.
First check-in call or message with the clinic. We're checking in formally, not just waiting for problems.

Week 5: Settling Into the New Dose

Same dose as week 4.
Energy levels often shift in week 5 — for the better, in most cases. Less post-meal sluggishness, less afternoon crash.
Watch for constipation. GLP-1s slow your gut down, and that includes the colon. More water, more fiber (psyllium husk or magnesium citrate at bedtime help).
Consider whether a daily multivitamin is in place. With reduced food intake, micronutrient gaps appear faster.

Week 6: Halfway Mark

Same dose as week 4-5.
Repeat Styku scan. This is the first real read on body composition change. Don't be discouraged if scale weight is moving slower than you'd hoped — the scan often shows substantial fat loss with muscle preservation, and that's the real win.
By week 6, most patients have lost 6-12% of their starting body weight if they're following the protocol. The exact number varies enormously, and slower losers often catch up later.
Check in: are workouts still happening? Is sleep on track? Is hydration consistent? The medication does its work, but the lifestyle pillars decide whether the work sticks.

Week 7: Continuing

Continue current dose, or escalate if appetite suppression has faded and weight loss has stalled. For semaglutide, we'd move from 0.5 mg to 1 mg. For tirzepatide, from 5 mg to 7.5 mg.
Whether to escalate is judgment. We don't escalate just because it's "the schedule" — we escalate based on response, side effects, and tolerance.

Week 8: The Two-Month Mark

Continue at current dose.
Many patients hit a plateau somewhere between weeks 6-10. This is normal. Bodies adapt. The plateau usually breaks within 2-3 weeks of holding course.
Don't panic-eat through a plateau. Don't abandon the protocol. Don't drop calories drastically — that just costs you muscle. Stay the course.
Resistance training intensity matters now. If you've been doing two or three light sessions a week, this is the week to add a third or fourth, or to add a little weight to the lifts.

Week 9: Habit Consolidation

Continue at current dose, or escalate again if the response has flattened.
By now, the food relationship has shifted noticeably. Patients describe being able to "eat like a normal person" — half a sandwich at lunch is genuinely satisfying, dessert isn't running through their head all afternoon, restaurants aren't a minefield.
This is the week we strongly recommend nailing down sleep. Consistent bedtime, dark room, no phone in bed. Sleep is the most underrated weight-loss tool we have.

Week 10: Real Progress Visible

Continue at current dose.
Most patients have lost 10-15% of their starting body weight by week 10 if they've been consistent. Some are higher.
Clothes fit differently. Faces look different. Energy is up. Joint pain is often noticeably down.
Repeat blood pressure check. Many patients see meaningful drops in systolic BP by week 10.

Week 11: Setting Up for Maintenance Thinking

Continue at current dose, or escalate one more time if response has flattened and tolerance is good.
Start thinking about what your maintenance phase will look like. Not because we're stopping — but because the patients who keep weight off long-term are the ones who think about it early.
Are the food habits going to hold without the medication's appetite suppression? Are the workout routines real and sustainable? Is the protein floor automatic by now? These are the maintenance questions.

Week 12: The Twelve-Week Review

Repeat Styku scan. Repeat lab panel (or partial — A1c, lipids, fasting insulin, CMP at minimum).
Repeat photos. Compare side-by-side with baseline. The visual difference at week 12 is, in most patients, the most motivating data they'll see.
Sit-down review with your provider. What's working, what isn't, what's the dose plan for the next twelve weeks, what's the body comp goal for month six.
If you've hit a goal weight ahead of schedule (some patients do), we start the maintenance conversation here. If you haven't, we map out the next phase.

Twelve weeks is a beginning, not an end. Most patients run a six- to twelve-month course on a GLP-1 protocol, with body composition tracking throughout, before transitioning to maintenance. We'll cover that further down. Want to start the clock? Call 662-331-6366 or book a consult.

Side Effects and How We Manage Them

Let's be honest about side effects. They're real, they're predictable, and they're almost always manageable. The patients who struggle most are the ones who weren't prepared for them. The patients who do best are the ones who knew what to expect and had a playbook ready. This is the playbook.

Nausea

The most common side effect by a wide margin. Usually mild, usually peaks 24-72 hours after each weekly dose, usually fades within the first month at any given dose. Re-intensifies briefly with each dose escalation.

Management:

Smaller portions. The nausea spikes when the stomach gets full faster than expected.
Lower-fat meals. Greasy food is the worst offender.
Slow eating. Put the fork down between bites.
Hydration — but sip, don't chug.
Ginger (tea, candies, capsules) genuinely helps for many patients.
If severe and persistent, we can prescribe ondansetron (Zofran) for breakthrough days.
If unmanageable, we slow the escalation schedule or hold at a lower dose for an extra week or two.

Constipation

The other side of slowed gut motility. Less talked about than nausea but often more persistent.

Management:

Water. Most patients aren't drinking enough. Aim for at least half your body weight in ounces, daily.
Fiber. Soluble fiber from psyllium husk (Metamucil or generic) at 5-10 grams daily makes a real difference.
Magnesium citrate, 200-400 mg at bedtime. Cheap, gentle, effective.
Movement. A daily walk does more for gut motility than people realize.
If stubborn, we'll occasionally add a stool softener temporarily.

GI Upset (General)

Bloating, mild cramping, the occasional bout of diarrhea. Usually peaks early and fades.

Management:

Smaller, more frequent meals if your appetite allows.
Avoid known triggers — for many people, that's dairy, very greasy food, alcohol, or carbonated drinks.
Probiotic if symptoms persist past the first month.

Fatigue

Some patients report a mild fatigue, especially in the first 2-3 weeks. Often this is actually a calorie deficit issue — when your appetite drops, you can accidentally undereat, and undereating tanks energy.

Management:

Make sure you're hitting your protein floor. This is the most common fix.
Don't let total calories crash. Even with reduced appetite, aim for at least 1,200-1,500 daily depending on body size and activity.
Check sleep — GLP-1s can occasionally disrupt sleep architecture in the first few weeks.
Check labs. Iron, vitamin D, B12, thyroid. Sometimes the fatigue isn't the medication.

Reflux

Slowed gastric emptying can worsen reflux for some patients. Usually manageable with positioning (don't lie down within 2-3 hours of eating), portion size, and occasionally a short course of an acid reducer.

Hair Shedding

Notable but usually temporary. Rapid weight loss of any kind can trigger telogen effluvium — a delayed shedding phase that shows up 2-4 months in. It's not the medication directly damaging hair; it's the body responding to the weight loss. Adequate protein, biotin if deficient, iron if low, and patience are the playbook. Hair almost always recovers.

Injection Site Reactions

Mild redness or itching at the injection site. Rotate sites (abdomen, thigh, upper arm) and the issue almost always resolves.

Rare and Serious Side Effects

Pancreatitis, gallbladder disease, severe allergic reactions, and a few others are rare but real. Severe abdominal pain that radiates to the back, persistent vomiting, signs of dehydration, or any rapid worsening is a call-immediately situation. We'll always make ourselves available for urgent questions.

The Food and Fitness Pillars That Make GLP-1 Work Better

This is the section most weight-loss articles skip, and it's the section that decides everything. The medication will reduce your appetite. What you do with that reduced appetite decides whether you end up at goal weight with strong muscle, healthy energy, and a body composition you're proud of — or 25 pounds lighter with sagging skin, weak legs, and the same metabolic problems waiting to come back.

The Protein Floor

Non-negotiable. Aim for 0.7-1.0 grams of protein per pound of goal body weight, daily. For most adults that lands somewhere between 100 and 180 grams a day. With reduced appetite from the medication, hitting this number requires intention. It does not happen by accident.

Practical anchors:

Eggs at breakfast. Two to four, plus one extra source (Greek yogurt, cottage cheese, a protein shake).
Lean meat at lunch. Chicken, turkey, lean beef, fish, tofu, lentils.
Lean meat at dinner. Same.
Protein shake or Greek yogurt as a snack if needed.

Protein protects muscle during weight loss. Muscle protects metabolism. Metabolism protects against weight regain. The chain is real and the protein floor is the first link.

Resistance Training

Lifting weights — or doing real bodyweight strength work — is the second link. We are not asking you to become a powerlifter. We are asking you to do something hard, with progressive load, for your major muscle groups, two to four times a week.

What "real" looks like:

Squats, lunges, or leg press — for your lower body.
Push-ups, dumbbell press, or push movements — for your chest and shoulders.
Rows, pull-downs, or pull-ups — for your back.
Some kind of core work — planks, dead bugs, leg raises.

Three sets of 8-12 reps per exercise, with weight that genuinely challenges you. Forty-five minutes, two to four times a week. That's it. No marathon training required.

Walking

Walking is underrated. 7,000-10,000 steps a day is the sweet spot for most adults. It's low-impact, doesn't trigger compensatory hunger the way intense cardio can, helps gut motility, and adds up to meaningful caloric expenditure without crushing recovery.

Sleep

Seven to nine hours, consistent timing, dark room, no phone. Poor sleep destroys insulin sensitivity, drives cortisol up, increases hunger hormones, and undoes the work of the medication. If you fix nothing else from this list, fix sleep.

Hydration

Aim for half your body weight in ounces, daily. More if you're sweating. Most patients walk into the clinic chronically under-hydrated and don't know it. Hydration also matters specifically on GLP-1 protocols because slowed gastric emptying plus reduced overall food intake (and the water that comes with food) can compound into mild chronic dehydration, which then shows up as fatigue, headaches, constipation, and cravings that get misread as hunger. The fix is so simple it's almost embarrassing — drink more water — but the patients who actually do it consistently outperform the ones who don't.

Fiber

Easy to ignore, hard to overstate. With reduced food intake, the obvious sources of fiber — vegetables, whole grains, beans, fruit — can get squeezed out of the day in favor of pure protein. The result is constipation, gut microbiome disruption, and worse satiety per calorie. We tell patients to aim for 25-35 grams of fiber daily, anchored around vegetables at lunch and dinner, a serving of berries or other low-sugar fruit somewhere, and a psyllium husk supplement if needed to fill the gap. The patients who get this right have noticeably fewer GI side effects and report better energy.

Alcohol

Alcohol while on a GLP-1 is generally fine in moderation, but a few notes. First, GLP-1s tend to dramatically reduce alcohol cravings — many patients spontaneously stop drinking or cut way back without trying, and that's worth paying attention to. Second, alcohol is empty calories that bypass the appetite-suppression machinery. Third, alcohol on a slowed gut can hit harder than usual. We're not anti-drink, but we tell patients: drink less than you think, eat protein with it, and stay hydrated.

Body Composition Tracking with Styku

The scale lies. Not literally — it's accurate to the gram — but it tells you only a tiny fraction of the story. Two pounds gone could be all fat, all muscle, all water, or some mix. The number doesn't tell you which.

Styku 3D body scanning, which we offer at our Corinth clinic, solves this. The patient stands on a turntable, the scanner takes about thirty seconds to capture a full 3D model, and the software outputs:

Body fat percentage (estimated, validated against DEXA-style measurements).
Lean mass.
Circumferences at every relevant site — neck, chest, waist, hips, thighs, arms, calves.
Volume changes by region.
Visceral fat estimate.
Side-by-side comparisons across scans, with color-coded mapping showing exactly where your body has changed.

Read more about body composition analysis on the dedicated services page, but the practical point: a patient who has "only" lost six pounds on the scale but four pounds of fat plus an inch off the waist is winning, full stop. The Styku catches that. The scale doesn't.

We scan at baseline, week 6, week 12, and roughly every six to eight weeks after. The data informs dosing decisions, food strategy, training intensity, and — most importantly — keeps motivation real on the weeks when the scale is being uncooperative.

What Twelve Weeks Realistically Looks Like — A Composite

Numbers help, but a composite picture often helps more. The patient described in the opening of this article — the one with eleven years of failed attempts behind her — would, on a typical semaglutide protocol with full follow-through, expect to see something like the following twelve-week arc.

By week 2, the food noise has quieted. She's not thinking about lunch at 10 AM anymore. She finishes about two-thirds of dinner portions she used to clean. Scale down 3 pounds. Energy roughly the same.

By week 4, after the first dose escalation, weight is down 7-9 pounds. Pants are slightly looser. The first comments from coworkers are starting to come. She's walking 25-30 minutes after dinner most nights, not because we made her, but because she has the energy to.

By week 8, weight is down 15-18 pounds. Resistance training has become a routine — three times a week at the local gym, basic dumbbell movements, nothing fancy. Body fat percentage on the Styku has dropped 3-4 percentage points. Lean mass is essentially unchanged, which is exactly what we want. Sleep is better. Joint pain in her knees that she'd just accepted as part of life is meaningfully less.

By week 12, weight is down 22-26 pounds. A1c, which started at 5.9 (the high end of prediabetic), has dropped into the 5.5 range. Triglycerides cut roughly in half. Resting heart rate down 8 beats per minute. Blood pressure normalized off her low-dose medication. She's lifting more weight than she did when she started, walking eight thousand steps a day without trying, and — the part she didn't expect — she likes the way she feels in clothes for the first time since her early twenties.

That's a typical twelve-week outcome for a patient who follows the protocol. Some patients lose more, some less. The point isn't to set a quota; the point is to show that the meaningful changes happen across many systems at once, and they happen faster than most patients believe is possible.

Maintenance and the Off-Ramp

Patients ask, almost universally: "Will I have to be on this forever?"

The honest answer is: maybe, maybe not, and the path depends on what you build during the active phase.

For some patients, GLP-1 therapy is more like a metabolic reset. They use the medication for 9-18 months, lose the weight they want to lose, build muscle, fix sleep, fix food habits, and then taper off — moving from weekly injections to every-other-week, then monthly, then off entirely. They keep the weight off because the underlying behaviors are now real.

For other patients — particularly those with significant insulin resistance, type 2 diabetes, or genetic predispositions to obesity — long-term low-dose maintenance makes more sense. The medication isn't a temporary intervention; it's a chronic-condition management tool, the same way a blood pressure medication is. There's nothing wrong with that. The biology that drove the weight gain doesn't go away just because the weight did, and using a tool to manage that biology is no different from using a CPAP for sleep apnea.

What we never recommend is stopping cold the day you hit goal weight. That's how regain happens. The taper is gradual, the lifestyle pillars are reinforced, and the body composition tracking continues. We typically discuss the off-ramp openly starting around month four or five, depending on the patient's progress and goals.

Why Cash-Pay and Why No Insurance

This is a conversation we have with most new patients. The short answer: we run a cash-pay membership model, we don't bill insurance for weight-loss medications, and there are real reasons for that.

Insurance coverage for GLP-1 weight-loss medications is, charitably, a mess. Coverage varies wildly by plan, denials are routine, prior authorizations take weeks, and even approved patients often face copays that are higher than our cash-pay membership pricing. We've watched clinics try to navigate it and watched patients spend months in coverage purgatory. We don't want to put our patients through that.

Membership pricing also lets us include things insurance would never cover anyway: regular Styku scans, lab interpretation calls, food strategy coaching, and the kind of unhurried follow-up time that real treatment requires. The number is what it is, and you'll see it on the consult — no surprise billing, no out-of-network gotchas, no "we'll see what your plan covers" runaround.

If you have an HSA or FSA, those funds usually cover us. If your insurance does cover branded semaglutide or tirzepatide and your copay is reasonable, we're happy to work with that — many of our patients use a hybrid approach. But our default is straightforward, transparent, cash-pay, and we think most patients prefer it once they see how it works. Read more about how the membership works.

The Corinth Clinic Experience

We opened the Corinth clinic about two weeks ago. It's the third location in the Impact Health Clinics network, after Oxford and Olive Branch. The address is 2107 S Harper Rd, Corinth, MS 38834. We're in the same plaza as the Walmart Supercenter, right next door to Cato Fashions. If you've ever picked up groceries on Harper Road, you've driven past us.

Parking: free, shared lot with the Walmart Supercenter. Pull in toward the Cato side of the lot and you'll see our sign.

Hours, currently: Tuesday and Wednesday, 9:00 AM to 5:00 PM. As demand grows we'll add days. Our Oxford and Olive Branch locations cover overflow if you need an appointment outside Corinth's current hours.

Phone: 662-331-6366. Email: info@impacthealthclinics.com.

What to bring to your first appointment:

Photo ID.
List of current medications and supplements.
Any recent labs (last 6-12 months) if you have them. We don't require them — we'll draw fresh ones — but they help with context.
Goals and questions. The more specific, the better.

Wear comfortable clothing. The Styku scan goes better with form-fitting clothing, but we have options if you're not prepared. The first visit takes about an hour. Subsequent follow-ups are typically 15-30 minutes.

The Corinth clinic is a real, in-person facility. It is not a virtual storefront with a PO Box. You can walk in, meet the team, see the equipment, and ask the questions you wouldn't ask a screen. That matters to most of our patients.

Read the opening announcement for more on the clinic itself, or browse all our locations.

Telehealth Follow-Ups for Northeast MS, TN, and AL

The first visit is in person. Subsequent follow-ups can usually be done via telehealth — secure video, scheduled at a time that works for you, with the same providers you saw in person.

For patients in Booneville, Rienzi, Glen, Kossuth, Farmington, and the broader Alcorn County area, telehealth means you don't have to make the drive every month. For patients across the state line in Tennessee or Alabama, the same applies — we can manage routine follow-ups remotely as long as we have a current in-person baseline.

Lab draws can be done at any reasonable lab partner local to you, or scheduled in-person at the Corinth clinic when you're due for a Styku scan anyway. We typically pair the in-person Styku scan with a fasting lab draw at the same visit, every six to twelve weeks, depending on protocol.

This hybrid model — in-person for milestones and exams, telehealth for routine follow-ups — is how most of our patients run after the first month or two.

Frequently Asked Questions

1. Will I gain it back when I stop?

Maybe. Maybe not. The studies on stopping GLP-1 medications cold show meaningful regain in many patients — typically 50-70% of the lost weight within 12 months of discontinuation, in the studies that put patients on no maintenance protocol. But those studies don't reflect what we actually do, which is gradually taper, reinforce lifestyle pillars, track body composition, and adjust as needed. The patients we've worked with who have done the work — built muscle, fixed sleep, real food habits — generally maintain. The patients who used the medication as a shortcut and didn't address anything else generally regain. The choice is more in your hands than the studies make it look.

2. What about muscle loss?

Real concern. Any rapid weight loss without adequate protein and resistance training will cost you muscle. The protein floor and the lifting protocol exist specifically to prevent this. Patients who follow them keep the vast majority of their muscle mass — and many actually gain muscle while losing fat, especially earlier in the journey. The Styku tracks this directly, so we know rather than guess.

3. Can I drink alcohol?

Yes, in moderation. Many patients find their alcohol cravings drop sharply once on a GLP-1 — that's a real and well-documented effect — but if you choose to drink, do it in moderation, eat protein with it, and stay hydrated. Heavy drinking on a GLP-1 is a bad idea: empty calories bypass the appetite-suppression machinery, alcohol on a slowed gut hits harder, and it can worsen GI side effects.

4. Do I need to exercise?

Yes. Not optional. The medication will reduce appetite and produce weight loss with or without exercise — but the weight you lose without exercise will include a meaningful percentage of muscle, and the body composition you end up with will be worse than the scale weight implies. Two to four resistance training sessions per week and daily walking is the floor. Less than that and you're leaving outcomes on the table.

5. Is compounded the same as branded?

Compounded semaglutide and tirzepatide use the same active ingredient as their branded counterparts, sourced from FDA-registered compounding pharmacies. Branded versions (Wegovy, Zepbound, Ozempic, Mounjaro) come from the original manufacturers and have the largest body of clinical trial data. Compounded versions are legitimate when sourced from reputable compounding pharmacies — and they've been a critical option during periods of branded shortage. Both work. The choice often comes down to availability, cost, and patient preference. We'll discuss the trade-offs at your consult.

6. How do you handle shortages?

We maintain relationships with multiple supply sources — branded and compounded — so we have flexibility. During the acute shortages of 2023-2024, our existing patients largely stayed on protocol because we had options. The supply situation is more stable now than it was, but we keep redundancy. If your specific medication becomes unavailable, we have pre-discussed switch options ready before it's a crisis.

7. Can I switch from semaglutide to tirzepatide mid-protocol?

Yes. It's a routine decision. The most common reasons to switch: persistent plateau on semaglutide, intolerable side effects we can't manage, or insurance/supply changes. The conversion is straightforward — we'd typically drop you to a lower starting dose of tirzepatide than your equivalent semaglutide and re-titrate. Most patients tolerate the switch easily and many see a meaningful re-acceleration of weight loss after the change.

8. Is this safe for pre-diabetics?

Pre-diabetics are arguably the population that benefits most from GLP-1 therapy. The medications were originally developed for diabetes care and have substantial evidence for delaying or preventing the progression from prediabetes to type 2 diabetes. If your A1c is in the prediabetic range (5.7-6.4) and you're carrying excess weight, you're a strong candidate. Many of our patients in this group see their A1c drop back into the normal range within the first six months.

9. Can I do this with TRT or HRT at the same time?

Yes, and many of our patients do. TRT for men and HRT for women interact synergistically with GLP-1 therapy in many cases — hormone optimization improves muscle preservation, energy, sleep, and the body composition outcomes of weight loss. We coordinate the protocols across providers and there's no clinical reason to do them sequentially when you can do them in parallel.

10. Will my insurance ever cover this?

Possibly. Coverage for branded GLP-1 weight-loss medications has been slowly expanding, but it remains plan-dependent and often subject to step-therapy and prior-authorization requirements. Some employer plans cover Wegovy or Zepbound for weight loss with reasonable copays; many don't. Coverage for the diabetes formulations (Ozempic, Mounjaro) for diabetic patients is more consistent. We don't bill insurance directly, but we can provide documentation to support your own claim if you'd like to pursue reimbursement.

11. What if I plateau?

Plateaus are normal. They happen to almost every patient at some point in the protocol. The first plateau usually shows up between weeks 6 and 10, the second around month four, and they get more frequent later in the journey as you approach a healthier set point. The playbook: hold the dose, reinforce protein and resistance training, check sleep and hydration, give it 2-3 weeks. If still stalled, we consider a dose escalation, a switch from semaglutide to tirzepatide, or a structured calorie audit. Plateaus break — they just don't always break on the timeline you'd prefer.

12. What about peptide therapy and NAD+ alongside this?

For some patients, yes — both can be useful adjuncts. Peptide therapy can support recovery, sleep, skin elasticity (relevant during rapid weight loss), and lean mass preservation. NAD+ therapy can support energy and metabolic function. These aren't required, and we don't push them — but they're available and we'll discuss whether they make sense in your protocol if you ask.

Closing CTA

If you've read this far, you're more prepared for a GLP-1 consult than 95% of the patients who walk in cold. You know what semaglutide and tirzepatide are, how they work, who's a candidate, what to expect from the first twelve weeks, what side effects look like, and what the lifestyle pillars require.

The next step is a real consult. We'll review your history, answer your specific questions, run the lab panel, do a baseline Styku scan, and put a real plan in front of you — one that fits your body, your goals, and your life in Corinth or Alcorn County or wherever in Northeast Mississippi you're driving in from.

Call us at 662-331-6366 or book online. The Corinth clinic is at 2107 S Harper Rd, in the Walmart Supercenter plaza next to Cato Fashions. Tuesday and Wednesday hours, 9 AM to 5 PM. We'll see you there.

Other entry points: read more about medical weight loss in Corinth, semaglutide, tirzepatide, our comprehensive lab panels, the peptide therapy options that pair well with GLP-1 protocols, or TRT if hormone optimization is on your radar too. The full blog archive has more on body composition, training, and recovery. Contact us with any questions and we'll get back to you fast.

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice. GLP-1 medications, including semaglutide and tirzepatide, carry specific contraindications, side effects, and risks that must be evaluated by a qualified healthcare provider in the context of your individual medical history. Individual results vary substantially. Outcomes described here are typical patterns observed in clinical practice, not guarantees. Do not start, stop, or modify any prescription medication without direct guidance from your treating provider. If you are pregnant, planning pregnancy, breastfeeding, or have a personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, or any of the other contraindications discussed, GLP-1 therapy may not be appropriate for you. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before beginning any new treatment protocol.